Current practices and challenges in implementing precision medicine for upper gastrointestinal cancers in European academic centers: an EORTC survey
María Alsina, Ana Elsa Huerta, Florian Lordick et al. · ESMO Gastrointestinal Oncology · 2024
Background: Precision oncology is gaining momentum in managing patients with gastrointestinal cancers. This study examines the implementation of personalized medicine technologies in upper gastrointestinal (UGI) oncology across European academic centers. Material and methods: Forty-five oncology specialists from 41 European institutions completed a survey designed by the Personalized Medicine Task Force of the European Organization of Research and Treatment of Cancer (EORTC) Gastrointestinal Tract Cancer Working Group, providing insights into molecular testing, timing, availability of targeted therapies, funding sources, and utilization of molecular tumor boards (MTBs) for patients with UGI cancers. Frequencies and percentages were calculated. Results: Routine testing for human epidermal growth factor receptor 2 (HER2, 100%), programmed death-ligand 1 (PD-L1, 89%), and DNA mismatch repair (MMR, 91%) is implemented in most centers. Comprehensive gene panels on tumor tissue are frequently utilized, especially in biliary tract cancer, with almost all centers incorporating them into routine practice. Blood-based sequencing is increasingly employed, and half of centers carry out comprehensive gene panels for circulating tumor DNA analyses. MTBs are regularly held in 76% of centers, predominantly utilizing ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)-based recommendations for tissue molecular alterations. The translation of genomic information into prescribed treatments remains limited, however, with the majority of centers reporting ∼25% of molecularly stratified treatment decisions following comprehensive genetic testing. Conclusion: This survey provides important insights into current personalized medicine practice in European academic clinical centers for UGI oncology. Despite widespread adoption of molecular testing and implementation of MTBs, further efforts are needed to optimize the integration of personalized medicine into clinical practice.
Cited by 4 works. doi:10.1016/j.esmogo.2024.100074 Open-access PDF
Authors
- María Alsina
- Ana Elsa Huerta
- Florian Lordick
- Sabine Verschueren
- Markus Hermann Moehler
- Elisa Fontana
- E.C. Smyth
- Francesco Sclafani
- Dorothea Wagner
- Lorenza Rimassa
- Ángela Lamarca
- Cindy Neuzillet
- Radka Lordick Obermannova
References
- The Sequence of the Human Genome
- First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
- A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
- Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up